Eli Lilly weight loss drug reduces diabetes risk

Eli Lilly’s popular weight loss drug, Zepbound, may reduce the risk of developing Type 2 diabetes by 94% in obese and overweight adults with prediabetes, according to preliminary results from a new long-term study published on Tuesday.

Lilly announced the top-line results from its three-year-long SURMOUNT-1 clinical trial evaluating the long-term safety and efficacy of tirzepatide, the active ingredient in the company’s weight loss drug.